All In Biotech

Drug Trial Radar · NCT06110676

A Study to Evaluate the Efficacy and Safety of LZM012

A Muti-center, Randomized, Double Blind, Positive Control Phase III Clinical Study to Evaluate the Efficacy and Safety of LZM012 in Moderate to Severe Chronic Plaque Psoriasis Patients

Last checked: Nov 19, 2026Latest source record: Nov 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 918 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

918

Planned (sponsor's estimate)

Start

Aug 21, 2023

Primary completion

Apr 2025

Study completion Jun 2025

Sponsor

Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients

Conditions

  • Psoriasis

Interventions

  • LZM012Biological

    Recombinant anti-human IL-17A/F humanized monoclonal antibody injection

  • SecukinumabBiological

    Cosentyx

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PASI100 response rateTime frame: At week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.